REGENXBIO Reports Third Quarter 2025 Financial Results and Operational HighlightsPRNewsWire • 11/06/25
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy ProgramPRNewsWire • 10/30/25
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2025 Financial Results and Operational HighlightsPRNewsWire • 10/29/25
REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual MeetingPRNewsWire • 10/09/25
REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMDPRNewsWire • 10/06/25
Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter SyndromeSeeking Alpha • 09/09/25
REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter SyndromeSeeking Alpha • 09/06/25
REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS IIPRNewsWire • 09/05/25
REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS IIPRNewsWire • 08/18/25
REGENXBIO Reports Second Quarter 2025 Financial Results and Operational HighlightsPRNewsWire • 08/07/25
REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic RetinopathyPRNewsWire • 08/07/25
REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational HighlightsPRNewsWire • 07/31/25
REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular DystrophyPRNewsWire • 07/10/25
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, LongerBenzinga • 06/05/25
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202PRNewsWire • 06/05/25
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202PRNewsWire • 06/02/25
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 MillionPRNewsWire • 05/19/25
FDA Accepts Biologics License Application for Mucopolysaccharidosis II TreatmentPRNewsWire • 05/14/25